Home > Investor Relations > Financial Results > Latest Results

Latest Results

April 25, 2017

FY2017 1Q Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
125,467 (61,167) (15,425) (19,255) (3,275)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
26,345 21.0 24,955 18,725 33.86

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
798,237 236,052 562,184 (35,842) (114,565)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
646,997 10.0 81.1 58.00 (Forecast) 29.00 (Forecast)

Revenues: 125.5 billion JPY (+5.6, +4.7% YoY)

Domestic sales excl. Tamiflu®: decrease due to impact of HIP revision (-2.7, -3.1%)
Overseas sales: increase of export of Alecensa® and Actemra® to Roche (+4.8, +23.1%)
Royalties and other operating income: increase in milestone income(+3.0 +69.8%)

Cost of sales / Operating expenses (Core basis)

Cost of sales: the ratio to sales improved due to change in product mix, etc. (-1.1% points, from 52.7% to 51.6%)
Operating expenses: slight overall decrease mainly due to the decrease of marketing and distribution expenses (-0.7, -1.8%)


IFRS results:  
operating profit  26.3 billion JPY (+6.2, +30.8%)
net income  18.7 billion JPY (+4.0, +27.2%)
Core results:  
operating profit  26.7 billion JPY (+6.3 +30.9%)
net income  18.9 billion JPY (+4.0, +26.8%)
EPS  34.22 JPY (+7.28, +27.0%)

Jan-Mar 2017 Sales excluding Tamiflu®

Core Operating Income Jan-Mar

*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.

More Information

To view PDF files,
you will need Adobe® Reader® which is available as a free download.